Compare Natera Inc. Common Stock (NTRA) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Vanguard Value Index Fund ETF — how do they compare? Natera Inc. Common Stock trades at $393.93 (market cap $57.03B), while Vanguard Value Index Fund ETF trades at $221.56 (market cap $262.40B). The key difference: Vanguard Value Index Fund ETF is far larger — about 4.6× Natera Inc. Common Stock's market cap, and Vanguard Value Index Fund ETF is more actively traded (2,800,630 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Vanguard Value Index Fund ETF for 143 Days on average.
| NTRA | VTV | |
|---|---|---|
Market Cap | $57.03B | $262.40B |
Volume | 1,131,157 | 2,800,630 |
Sector | Health | — |
52-Week High | $425.64 | $227.51 |
52-Week Low | $179.42 | $182.89 |
Typical Hold Time | 0 Days | 143 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
VTV trades at $220.67, down 0.34% on the day, with a bullish technical signal supported by moving averages but mixed oscillators. The ETF shows strong institutional interest with recent acquisitions by QRG Capital Management and Blue Edge Capital. Recent news highlights VTV's 2.3% dividend yield and value-focused strategy outperforming growth counterparts in 2026, with value stocks gaining traction amid market rotation away from tech concentration.
VTV presents a compelling value proposition with low 0.03% fees and income appeal, though long-term performance trails the S&P 500. Key risks include sustained growth stock dominance and interest rate sensitivity. The ETF's diversification across value stocks positions it well for investors seeking stability amid market uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
